Garcia-Verdugo Rosa, Erbach Michael, Schnell Oliver
1 Sciarc Institute, Baierbrunn, Germany.
2 Forschergruppe Diabetes e.V., Munich-Neuherberg, Germany.
J Diabetes Sci Technol. 2017 Jul;11(4):814-821. doi: 10.1177/1932296817694913. Epub 2017 Mar 1.
In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.
近年来，持续腹腔内胰岛素输注（CIPII）已成为皮下胰岛素抵抗患者青睐的一种治疗选择，主要是因为它能够模拟胰岛素吸收的生理状态。CIPII已被证明可改善血糖控制，减少低血糖事件，并提高患者满意度和生活质量（QoL）。在CIPII输送系统中，Diaport因其副作用低、已证实的临床疗效以及集成到闭环系统的潜力而脱颖而出。
